Latest news with #AnthemBiosciences
&w=3840&q=100)
Business Standard
2 days ago
- Business
- Business Standard
Anthem Biosciences lists at 27% premium; should you book profit or hold?
Anthem Biosciences IPO listing, Anthem Biosciences share price: Shares of innovation-driven and technology-focused company Anthem Biosciences made a solid D-Street debut on Monday, July 21, following the completion of its initial public offering (IPO). The company's shares listed at ₹723.10 per share on the BSE, reflecting a premium of ₹153.10 or 26.86 per cent over the issue price of ₹570 per share. On the National Stock Exchange (NSE), Anthem Biosciences shares listed at a mildly lower premium of ₹153.05 or 26.85 per cent at ₹723.05 per share over the issue price. Anthem Biosciences IPO listing came below the grey market estimate. Ahead of their debut on the bourses, the unlisted shares of Anthem Biosciences were exchanging hands at around ₹749 per share, reflecting a grey market premium (GMP) of ₹179 per share or nearly 31.40 per cent over the issue price of ₹570 per share, showed the sources that track unofficial market activities. Should you book profit or hold? The listing of the company's shares, Prashanth Tapse, senior VP (research), Mehta Equities, said was broadly in line with expectations. While post-listing valuations may appear premium, Tapse believes these are justified by the company's strong fundamentals, differentiated capabilities, and the sector's long-term growth visibility. "The ability to consistently deliver earnings growth, in line with street expectations, further supports its valuation," said Tapse, and recommended investors to 'hold' Anthem Biosciences for a long-term perspective. "For long-term investors, Anthem offers a strong structural story in a booming Indian CRDMO segment, justifying the listing. Short term, we foresee ₹900 as a target, while long-term investors can hold it for ₹1,000 and above. Non-allottees should wait for some volatility to settle in price, and in any case, if the stock is available around ₹650–680, it can be considered a good range to accumulate with a long-term vision," said Tapse. Shivani Nyati, head of wealth at Swastika Investmart, on the other hand, recommended investors to secure partial profits. "The company is one of the leading global players in the CRDMO segment and enjoys a niche position, leading the pack of players. The company has shown steady growth in its top line during the reported periods," said Nyati. She further recommended the investors to retain the remaining stake with a stop-loss set at ₹650. Anthem Biosciences IPO details Anthem Biosciences IPO comprised entirely an offer-for-sale (OFS) with promoters and shareholders divesting up to 59.6 million equity shares estimated to be worth ₹3,395 crore. The public issue was offered at a price band of ₹540–570 with a lot size of 26 shares, and was open for subscription from July 14, 2025, till July 16, 2025. Anthem Biosciences received strong demand from investors for its public issue as it got oversubscribed by 63.86 times. The demand was led by the qualified institutional buyers (QIBs), who bid for 182.65 times the category reserved for them, showed the NSE data. Anthem Biosciences, as outlined in its red herring prospectus (RHP), will not use any proceeds from the public issue, and it will be given to the promoters and shareholders selling their stakes through the OFS. About Anthem Biosciences Incorporated in 2006, Anthem Biosciences is a contract research, development, and manufacturing organisation (CRDMO) serving global customers. The company manufactures specialised fermentation-based APIs, including probiotics and enzymes. Anthem Biosciences has a diverse customer base, including biotech firms and large pharmaceutical companies, spanning over 44 countries. As of September 2024, the company had 196 projects and over 425 customers in its CRDMO business. The company holds one patent in India and seven overseas, with 24 pending global patent applications.
Mint
2 days ago
- Business
- Mint
Anthem Biosciences share price gains after strong listing. Should you buy, sell or hold the stock?
Anthem Biosciences share price made a stellar debut in the Indian stock market today, July 21, after its initial public offering (IPO) received a strong demand. Anthem Biosciences shares listed at ₹ 723.05 apiece on the NSE, a premium of 26.85% over the issue price of ₹ 570 per share. On BSE, Anthem Biosciences share price opened at ₹ 723.10 apiece, higher by 26.86% from the IPO price. Anthem Biosciences is a manufacturer of specialised fermentation-based APIs, and its IPO was heavily oversubscribed. Anthem Biosciences IPO listing date was today, July 21, 2025. Anthem Biosciences IPO listing was in line with the Street estimates, as indicated by the grey market premium (GMP). Anthem Biosciences IPO GMP today, and analysts had signalled a strong debut of shares. Here's what investors should do after Anthem Biosciences' share listing today. Mahesh M. Ojha, AVP - Research & Business Development at Hensex Securities, advises short-term investors who were allotted shares to consider booking partial profits as he believes over 25% gain at listing is substantial, and booking gains allows for risk management. 'Long-term investors should focus on the company's growth roadmap. Anthem has strong fundamentals, but future performance will depend on margin sustainability, innovation pipeline, and global client growth. For investors who missed the IPO, it would be wise to wait for a few trading sessions. Once the stock stabilises, it may offer a better entry point based on earnings visibility and peer comparison,' Ojha said. According to Prashanth Tapse, Sr. VP Research at Mehta Equities, Anthem Biosciences made a healthy debut, broadly in line with expectations, reflecting strong investor appetite. 'While post-listing valuations may appear premium, we believe these are justified by the company's strong fundamentals, differentiated capabilities, and the sector's long-term growth visibility. The ability to consistently deliver earnings growth, in line with street expectations, further supports its valuation,' Tapse said. Hence, looking at its all financial as well as sectorial, he recommends investors to 'Hold' Anthem Biosciences shares for a long-term perspective. 'For long-term investors, Anthem offers a strong structural story in a booming Indian CRDMO segment, justifying the listing. In the short term, we foresee ₹ 900 as the target for Anthem shares, while long-term investors can hold it for ₹ 1,000 and above. Non-allottees can wait for some volatility to settle in price, and in any case, if the stock is available around ₹ 650-680, it can be considered a good range to accumulate with a long-term vision,' Tapse said. Shivani Nyati, Head of Wealth at Swastika Investmart, recommends investors to secure partial profits and retain the remainder with a stop-loss set at ₹ 650. Anthem Biosciences IPO was open from July 14 to July 16. The IPO was subscribed 63.86 times in total, as per the NSE subscription data. The retail portion was booked 5.64 times, while the Non-Institutional Investors (NII) segment was subscribed 42.36 times. The Qualified Institutional Buyers (QIBs) category received 182.65 times subscription. At 12:25 PM, Anthem Biosciences' share price was trading at ₹ 728.90 apiece on the BSE, up by 0.80% from its listing price, and up 27.88% from its issue price.
Time of India
2 days ago
- Business
- Time of India
Anthem Biosciences soars on debut: Shares jumps 3% after healthy listing - Should you buy now?
Anthem Biosciences shares surged 3.3% to Rs 746.70 during Monday's intraday trading session on BSE, after making a strong debut with a 27% premium over its IPO price. The company's IPO investors are now sitting on overall gains of around 31%, ET reported. The stock market welcomed Anthem Biosciences with a robust listing premium of 26.84%, opening at Rs 723 compared to its issue price of Rs 570. The IPO received an extraordinary response with 67.42 times subscription across investor categories. The offering consisted entirely of an offer for sale, with proceeds directed to existing shareholders. Prior to the public offering, anchor investors contributed Rs 1,016 crore. Should you buy the shares now? Prashanth Tapse, Senior VP (Research) at Mehta Equities, told ET that, "While post-listing valuations may appear premium, we believe these are justified by the company's strong fundamentals, differentiated capabilities, and the sector's long-term growth visibility." Based on the company's financial performance and industry position, he further advised investors to "HOLD" Anthem Biosciences with a long-term outlook. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Fastest Selling Plots of Mysore from 40L | 40+ Amenities PurpleBrick Learn More Undo "For long-term investors, Anthem offers a strong structural story in a booming Indian CRDMO segment, which justifies the listing," he noted. The analysis suggests a short-term target of Rs 900, whilst long-term investors might consider holding for Rs 1,000 and beyond. For those who missed the IPO allocation, it's advisable to wait for price stabilisation, ET reported. Established in 2006, Anthem's operations span across drug discovery, development, and commercial manufacturing for both small molecules and biologics. The company's FY25 financial performance showed revenue growth of 30% to Rs 1,930 crore and profit increase of 23% to Rs 451 crore. EBITDA stood at Rs 684 crore with a 37% margin, maintaining minimal debt levels. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Mint
2 days ago
- Business
- Mint
Anthem Biosciences share price gains after strong listing. Should you buy, sell of hold the stock?
Anthem Biosciences share price made a stellar debut in the Indian stock market today after its initial public offering (IPO) received strong demand. Anthem Biosciences shares were listed at ₹ 723.05 apiece on the NSE, a premium of 26.85% to the issue price of ₹ 570 per share. On BSE, Anthem Biosciences share price opened at ₹ 723.10 apiece, higher by 26.86% from the IPO price. Anthem Biosciences is a manufacturer of specialized fermentation-based APIs and its IPO was heavily oversubscribed. Anthem Biosciences IPO listing date was today, 21 July 2025. Anthem Biosciences IPO listing was in line with the Street estimates as indicated by the grey market premium (GMP). Anthem Biosciences IPO GMP today ahead of the listing and analysts had signalled a strong debut of shares. Here's what investors should do after Anthem Biosciences share listing today. Mahesh M. Ojha, AVP - Research & Business Development at Hensex Securities Pvt. Ltd. advises short-term investors who were allotted shares to consider booking partial profits as he believes over 25% gain at listing is substantial, and booking gains allows for risk management. 'Long-term investors should focus on the company's growth roadmap. Anthem has strong fundamentals, but future performance will depend on margin sustainability, innovation pipeline, and global client growth. For investors who missed the IPO, it would be wise to wait for a few trading sessions. Once the stock stabilizes, it may offer a better entry point based on earnings visibility and peer comparison,' Ojha said. According to Prashanth Tapse, Sr Vp Research & Research Analyst at Mehta Equities Ltd, Anthem Biosciences made a healthy debut, broadly in line with expectations, reflecting strong investor appetite. 'While post-listing valuations may appear premium, we believe these are justified by the company's strong fundamentals, differentiated capabilities, and the sector's long-term growth visibility. The ability to consistently deliver earnings growth, in line with street expectations, further supports its valuation,' Tapse said. Hence, looking at its all financial as well as sectorial, he recommends investors to 'Hold' Anthem Biosciences shares for long-term perspective. 'For long-term investors, Anthem offers a strong structural story in a booming Indian CRDMO segment, justifying the listing. Short term we foresee ₹ 900 as target while long term investors can hold it for ₹ 1,000 and above. Non allottees wait for some volatility to settle in price and in any case if the stock is available around ₹ 650-680, can be considered a good range to accumulate with long term vision,' Tapse said. Shivani Nyati, Head of Wealth at Swastika Investmart Ltd. recommends investors to secure partial profits and retain the remainder with a stop-loss set at ₹ 650. Anthem Biosciences IPO was open from July 14 to July 16. The IPO was subscribed 63.86 times in total, as per the NSE subscription data. The retail portion was booked 5.64 times, while the Non Institutional Investors (NII) segment was subscribed 42.36 times. The Qualified Institutional Buyers (QIBs) category received 182.65 times subscription. At 12:25 PM, Anthem Biosciences share price was trading at ₹ 728.90 apiece on the BSE, up by 0.80% from its listing price, and up 27.88% from its issue price. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Mint
2 days ago
- Business
- Mint
Anthem Biosciences shares make robust debut, list at ₹723.05 on NSE, up 26.85% from IPO price
Anthem Biosciences IPO listing: Shares of Anthem Biosciences made a stellar debut on the bourses on Monday, July 21, listing at ₹ 723.05 on NSE, a premium of 26.85 percent over its IPO price of ₹ 570. Meanwhile, on BSE, it listed at ₹ 723.10, up 26.86 percent from issue price. The initial public offering (IPO), with a total issue size of ₹ 3,395.79 crore, was open for bidding from July 14 to July 16. The offering received an robust response from investors, closing with a subscription of 67.42 times. The IPO attracted bids for 281.49 crore shares compared to the 4.17 crore shares on offer. The retail investor category was subscribed 5.98 times while the non-institutional investor (NII) segment witnessed 44.70 times subscription. Meanwhile, the qualified institutional buyer (QIB) portion was bid the most, 192.80 times. Meanwhile, the employee quota was booked 6.99 times in this period. The IPO was entirely an offer for sale of 5.96 crore shares with no offer-for-sale. The lot size for the IPO was fixed at 26 shares, with the minimum investment for retail investors set at ₹ 14,040. The issue also included a reservation of up to 1,58,653 shares for employees offered at a discount of ₹ 50.00 to the issue price. As the IPO is completely an OFS, the company will not acquire any funds from the offering, and the proceeds will be directed to the selling shareholders. Ahead of the public offering, the company successfully raised ₹ 1,016 crore from anchor investors on July 11. JM Financial Limited was the book-running lead manager for the issue, while Kfin Technologies was its registrar. Founded in 2006, Anthem Biosciences Limited is a technology-led, innovation-centric Contract Research, Development, and Manufacturing Organization (CRDMO) offering end-to-end services across drug discovery, development, and manufacturing. The company caters to a broad global clientele, ranging from emerging biotech startups to leading pharmaceutical giants. Anthem Biosciences is engaged in the production of niche, fermentation-based active pharmaceutical ingredients (APIs), including probiotics, enzymes, peptides, nutritional ingredients, vitamin analogues, and biosimilars. The company's listed peers are Syngene International Ltd (with a P/E of 51.54), Sai Life Sciences Ltd (with a P/E of 92.18), Cohance Lifesciences Ltd (with a P/E of 97.29), and Divi's Laboratories Ltd (with a P/E of 83.22). In the financial year 2024-25, the company reported a 30 percent year-on-year growth in revenue from operations, which rose to ₹ 1,844 crore from ₹ 1,419 crore in FY24. Its profit after tax stood at ₹ 451 crore for the year ended March 31, 2025, reflecting a 23 percent increase compared to the previous year.
